
Celgene hires new medical director
pharmafile | November 12, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Celgene, kilcoyneÂ
Biopharma firm Celgene has announced the appointment of Dr Adrian Kilcoyne as its new medical director.
He will take up this position immediately and replace Dr David Gillen who has been promoted into the new role of head of Global Drug Safety and Risk Management.
Kilcoyne previously held leadership roles at Baxter Healthcare and Roche and joins the firm from Sanofi Pasteur MSD, where he was their medical director.
Kilcoyne’s pharma career started in 2006, when he joined Eli Lilly as a senior clinical research physician specialising in diabetes. Prior to that, he worked in both primary and secondary care, firstly as a specialist registrar in reproductive medicine and then practising as a GP for five years.
Kilcoyne said: “Celgene is making great strides for people with cancer and other immunological and inflammatory conditions and I’m looking forward to joining an organisation so committed to innovation and change. The progress they have made over the last few years has been really impressive and I’m confident that this will continue.”
Samantha Pearce, general manager of Celgene UK and Ireland, added: “We are delighted that Dr Kilcoyne has joined our organisation. He brings with him a wealth of experience that will prove a significant addition to the team, enabling us to continue to build on the already great work we are doing.”
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






